🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being viewed as a "major milestone" in the battle against drug-resistant strains of the infection, according to health experts.

A Worldwide Challenge

Gonorrhoea infections are escalating around the world, with data suggesting over 82 million instances per year. Particularly high rates are reported in the African continent and countries within the World Health Organization's designated area, which encompasses Mongolia and China to New Zealand. Within England, cases have hit a historical peak, while figures across Europe in 2023 were three times higher compared to those in 2014.

“The approval of new treatments for gonorrhoea is an critical and opportune advancement in the context of growing infection rates, escalating drug resistance and the extremely scarce available drugs at this time.”

Medical experts are particularly alarmed about the surge in treatment-resistant strains. The global health body has classified it as a "high-priority threat". Ongoing monitoring found that resistance to primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Therapies Secure Clearance

One new antibiotic, marketed under the name Nuzolvence, was cleared by the US Food and Drug Administration in mid-December for treating gonorrhoea. This disease can lead to serious health problems, including the inability to conceive. Experts anticipate that targeted use of this new drug will help hinder the spread of drug resistance.

Another new antibiotic, originating from the pharmaceutical company GlaxoSmithKline, was also approved in the same week. This drug, which is also used to treat urinary tract infections, was proven in research to be effective against superbug versions of the gonorrhoea bacteria.

A Novel Development Model

This new treatment emerged from a new, not-for-profit approach for drug creation. The charitable organization GARDP partnered with the pharmaceutical company Innoviva to develop it.

“This approval marks a huge turning point in the management of superbug gonorrhoea, which until now has been outpacing medical innovation.”

Clinical Trial Data and Global Access

As per results released by a prominent scientific publication, zoliflodacin cured the vast majority of cases of the STI. This puts it on an equal footing with the current standard treatment, which involves two antibiotics. The study included hundreds of participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, GARDP has the ability to make available and distribute the drug in many regions with limited resources.

Clinicians on the front lines have shared positive views. Having a single-dose, oral treatment of this kind is seen as a "revolutionary step" for managing the epidemic. This is deemed crucial to reduce the burden of the infection for individuals and to halt the transmission of extremely resistant gonorrhoea globally.